Factors influencing Human papillomavirus (HPV) vaccination series completion in Mississippi Medicaid

Sushmitha Inguva; Marie Barnard; Lori M Ward; Yi Yang; Eric Pittman; Benjamin F Banahan 3rd; Terri R Kirby; Sara L Noble

doi:10.1016/j.vaccine.2019.12.030

Factors influencing Human papillomavirus (HPV) vaccination series completion in Mississippi Medicaid

Vaccine. 2020 Feb 18;38(8):2051-2057. doi: 10.1016/j.vaccine.2019.12.030. Epub 2020 Jan 21.

Authors

Sushmitha Inguva¹, Marie Barnard², Lori M Ward³, Yi Yang², Eric Pittman⁴, Benjamin F Banahan 3rd⁴, Terri R Kirby⁵, Sara L Noble⁵

Affiliations

¹ Department of Pharmacy Administration, School of Pharmacy, University of Mississippi, University, MS 38677, USA. Electronic address: singuva@go.olemiss.edu.
² Department of Pharmacy Administration, School of Pharmacy, University of Mississippi, University, MS 38677, USA.
³ Department of Population Health Science, John D. Bower School of Population Health, University of Mississippi Medical Center, Jackson, MS 39216, USA.
⁴ Center for Pharmaceutical Marketing and Management, Research Institute for Pharmaceutical Sciences, University of Mississippi, University, MS 38677, USA.
⁵ Mississippi Division of Medicaid, Jackson, MS 39201, USA.

PMID: 31980196
DOI: 10.1016/j.vaccine.2019.12.030

Abstract

Purpose: To identify factors associated with Human Papillomavirus (HPV) vaccine series completion among vaccine initiators in Mississippi Medicaid.

Methods: 2013-2018 Mississippi Medicaid administrative claims data were analyzed. Female and male beneficiaries aged 9 to 26 years who initiated HPV vaccination in the identification period were assessed for completion of age-appropriate number of recommended doses within a period of 12 months. Sex-stratified multivariable logistic regression was used to examine factors associated with HPV vaccine series completion in the study sample.

Results: A total of 18,110 female and 18,186 male beneficiaries initiated HPV vaccine between January 1, 2014 and June 30, 2017. Most of the initiators belonged to ages 11 to 12 years, African American race, managed care plans and Central Mississippi public health region. The vaccine series completion rate was 34% for females and 30% for males. Younger age at initiation was a significant predictor of vaccine series completion in both sexes. Specifically, initiators in age groups 9 to 10 and 11 to 12 years, respectively, had greater odds of completion, while initiators aged 15 to 26 years had lower odds of completion compared to initiators aged 13 to 14 years. Female and male beneficiaries in managed care plans (vs. fee-for-service) and of African American race (vs. Caucasians) had lower odds of completing the vaccine series. Female and male beneficiaries who initiated HPV vaccine series with a pediatrician had the highest completion rates.

Conclusion: HPV vaccination series completion rate in Mississippi Medicaid was suboptimal despite the high HPV-related cancer incidence in the state. HPV vaccine series completion is influenced by various sociodemographic factors. There is a need for robust education and public health programs to encourage completion of recommended doses.

Keywords: Geographic factors; Human papillomavirus; Immunization; Medicaid; Sociodemographic factors; Vaccine initiation; Vaccine series completion.

MeSH terms

Adolescent
Adult
Black or African American
Child
Female
Humans
Immunization Schedule*
Infant
Male
Medicaid
Mississippi / epidemiology
Papillomavirus Infections* / epidemiology
Papillomavirus Infections* / prevention & control
Papillomavirus Vaccines / administration & dosage*
United States / epidemiology
Vaccination / statistics & numerical data*
White People
Young Adult

Substances

Papillomavirus Vaccines